CLL

Lilly to present positive Phase 3 results for pirtobrutinib in CLL at EHA 2026

Phase III Trial of Early Treatment in High-Risk CLL/SLL Shows Promise

The EVOLVE CLL/SLL study is comparing early versus delayed treatment with venetoclax and obinutuzumab in high-risk CLL/SLL patients.

Nemtabrutinib Study vs Ibrutinib/Acalabrutinib in 1L CLL/SLL Initiated

A study is underway to evaluate nemtabrutinib against ibrutinib or acalabrutinib in treatment-naive CLL/SLL patients.

Study Evaluates Outcomes After Discontinuation of BTK Inhibitors in CLL Patients

A Phase II study is assessing the outcomes of stopping BTK inhibitor therapy in CLL patients in remission for over two years.

Lilly's Jaypirca shows 45% reduction in disease progression risk in CLL/SLL

Jaypirca (pirtobrutinib) significantly reduced the risk of disease progression or death by 45% when added to a venetoclax regimen in previously treated CLL/SLL patients.